drugset / Trial / NCT02388061

Tenecteplase Versus Alteplase Before Endovascular Therapy for Ischemic Stroke

NCT02388061

RandomizedParallel-groupOpen-labelTreatment

Summary

Patients presenting to the emergency department with acute ischemic stroke, who are are eligible for standard intravenous tPA therapy within 4.5 hours of stroke onset will be assessed for major vessel occlusion to determine their eligibility for randomization into the trial. If the patient gives informed consent they will be randomised 50:50 using central computerised allocation to intravenous alteplase or tenecteplase before all participants undergo intra-arterial clot retrieval. The trial is prospective, randomised, open-label, blinded endpoint (PROBE) design.

Timeline

Start
2015-03-23
Primary completion
2017-10-16
Completion
2018-02

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Alteplase Protein / enzyme biologic 0.9 mg/kg Intravenous
Subject Tenecteplase Protein / enzyme biologic 0.25 mg/kg Intravenous

Indications